Lancet requires free registration prior to providing access. “Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer’s disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial,” by Prof. Richard Dodel, Axel Rominger, Peter Bartenstein, Frederik Barkhof, Kaj Blennow, Stefan Forster, Yaroslav Winter, Jan-Philipp Bach, Julius Popp, Judith Alferink, Jens Wiltfang, Katharina Buerger, Markus Otto, Piero Antuono, Michael Jacoby, Ralph Richter, James Stevens, Isaac Melamed, Jerome Goldstein, Stefan Haag, Stefan Wietek, Martin Farlow, and Frank Jessen (Vol. 12, No. 3, March 2013, p. 233-243).
www.thelancet.com/journals/laneur/article/PIIS1474-4422(13)70014-0/abstract
